Bayer AG has moved to answer critics concerned about the state of its late-stage pipeline by bagging the European rights to acoramidis, BridgeBio Pharma, Inc.'s closely watched potential blockbuster for transthyretin amyloid cardiomyopathy (ATTR-CM).
The German group is paying up to $310m comprising of upfront and near-term milestone payments, as well as additional undisclosed sales milestones, plus royalties beginning in the low-thirties percent on sales of acoramidis in Europe
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?